IDH2 and brain cancer: The novel PTEN-independent mode of mTORC1/2 activation via mutated IDH/2HG/KDM4A/DEPTOR revealed here may provide an additional molecular explanation for the oncogenic activity of IDH1/2 mutation in brain cancer.